Results 161 to 170 of about 1,442,988 (353)
ABSTRACT Fanastomig (also known as EMB‐02) is a bispecific antibody targeting programmed cell death protein‐1(PD‐1) and lymphocyte activation gene‐3 (LAG‐3), developed for the treatment of advanced solid tumors. A first‐in‐human (FIH) Phase I study (NCT04618393) evaluated safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD ...
Chengjun Jiang+6 more
wiley +1 more source
Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences [PDF]
To build effective therapeutics, biologists iteratively mutate antibody sequences to improve binding and stability. Proposed mutations can be informed by previous measurements or by learning from large antibody databases to predict only typical antibodies.
arxiv
Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model [PDF]
Isabelle Renard+6 more
openalex +1 more source
ABSTRACT The administration of biologics can lead to immunogenic responses that trigger anti‐drug antibody (ADA) formation. ADAs can decrease drug exposure. A population pharmacokinetic (popPK) model was developed to describe clinical PK data with and without ADA‐driven exposure loss with CEA‐directed T‐cell bispecific antibody cibisatamab.
Javier Sanchez+6 more
wiley +1 more source
Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal outcomes with subsequent therapies.
Ricardo D. Parrondo+2 more
doaj +1 more source
Relation-Aware Equivariant Graph Networks for Epitope-Unknown Antibody Design and Specificity Optimization [PDF]
Antibodies are Y-shaped proteins that protect the host by binding to specific antigens, and their binding is mainly determined by the Complementary Determining Regions (CDRs) in the antibody. Despite the great progress made in CDR design, existing computational methods still encounter several challenges: 1) poor capability of modeling complex CDRs with
arxiv
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer [PDF]
Roland Repp+14 more
openalex +1 more source
ABSTRACT Model simplification is a process to simplify large‐scale mathematical models to enable easy applications such as simulation and parameter estimation. A novel heuristic machine analogy method of model simplification was developed and applied to a motivating example of a model for cAMP signaling switch induced by Gi/Gs pathway competition for ...
Liang Yang+3 more
wiley +1 more source
Intradiabodies, Bispecific, Tetravalent Antibodies for the Simultaneous Functional Knockout of Two Cell Surface Receptors [PDF]
Nina Jendreyko+6 more
openalex +1 more source